CLINICAL TRIALS PROFILE FOR LIOTHYRONINE SODIUM
✉ Email this page to a colleague
All Clinical Trials for liothyronine sodium
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004062 ↗ | Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-07-01 | RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer. |
NCT00004062 ↗ | Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer | Completed | Lucille P. Markey Cancer Center at University of Kentucky | Phase 1 | 1999-07-01 | RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer. |
NCT00027417 ↗ | Study of Triostat in Infants During Heart Surgery | Completed | Michael Portman | Phase 3 | 2001-04-01 | This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. |
NCT00098852 ↗ | Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer | Unknown status | National Cancer Institute (NCI) | Phase 2 | 2004-10-01 | RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer. |
NCT00098852 ↗ | Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer | Unknown status | University of California, San Francisco | Phase 2 | 2004-10-01 | RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for liothyronine sodium
Condition Name
Clinical Trial Locations for liothyronine sodium
Trials by Country
Clinical Trial Progress for liothyronine sodium
Clinical Trial Phase
Clinical Trial Sponsors for liothyronine sodium
Sponsor Name